Biotech merger creates £280m group

Two of the UK's richest biotech companies unveiled a surprise merger yesterday in a move hailed as a significant breakthrough for a sector long in need of consolidation.

Cambridge Antibody Technology is buying Oxford GlycoSciences in an all-share deal to create a £280m group developing new drugs for rheumatoid arthritis, cancer and allergies.

David Ebsworth, chief executive of OGS, won praise from investors for agreeing to give up the top job, breaking the mould of biotech bosses who have often been seen as putting egos in the way of consolidation.

After six months helping integrate the two loss-making companies, Mr Ebsworth will become a non-executive director of the enlarged CAT, which will have a cash pile of £260m to pursue new drug development work and to licence in new products.

CAT's shareholders will own 64 per cent of the combined company and Peter Chambré, its chief executive, will lead the enlarged group.

Mr Chambré said: "We are both highly regarded companies in the UK, but when you compare us to the top tier of global biopharmaceutical groups there is quite a gap. It is a gap which we wish to close and our ability to do that will be enhanced by this merger." He argued that drug discovery technologies at the core of the two companies would fit well together. OGS is an expert in proteomics, and as such is able to identify proteins in the human body which may be linked to disease. CAT's expertise is in the identification and manufacture of antibodies, which are formed in the human body to fight disease.

The merged group will have seven products being trialled on humans and another seven in pre-clinical development. Both companies also bring one finished product: CAT's Humira is a treatment for rheumatoid arthritis which is ready for launch in the US, and OGS's Zavesca treats Gaucher disease, a rare condition in which the body has difficulty breaking down fat. Zavesca is approved in Europe but has been held up by sceptical US regulators.

The group still needs to broaden that pipeline of drugs if it is to reach profitability within five years, as Mr Chambré has promised. Although CAT is now more likely to buy in individual products than other companies, he said further deals could be expected when OGS was integrated.

CAT is targeting £10m of annual cost savings from cutting administrative staff at OGS in Oxford and selling property. There will also be a cull of the least exciting drug development work to save further cash and the combined group is expected to have an annual cash burn of about £50m.

The biotech industry has fallen as dramatically from investor favour as internet companies. The UK sector has suffered a chronic shortage of funds and few investors believe many businesses will survive to turn a profit. CAT has tumbled from £29 at its peak and fell a further 40p to 500p yesterday. OGS is down from £48, but jumped 32.5p to 185p on news of the takeover.

The deal was sealed after CAT settled two long-standing patent disputes last month.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Sport
Adnan Januzaj and Gareth Bale
footballManchester United set to loan out Januzaj to make room for Bale - if a move for the Welshman firms up
Arts and Entertainment
Lena Headey as Cersei Lannister in Game of Thrones
film
News
i100
Sport
Yaya Sanogo, Mats Hummels, Troy Deeney and Adnan Januzaj
footballMost Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
News
Nigel Farage celebrates with a pint after early local election results in the Hoy and Helmet pub in South Benfleet in Essex
peopleHe has shaped British politics 'for good or ill'
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Selby Jennings: VP/SVP Credit Quant- NY- Investment Bank

Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...

Selby Jennings: Quantitative Research | Equity | New York

Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...

Selby Jennings: SVP Model Validation

Not specified: Selby Jennings: SVP Model Validation This top tiered investment...

Selby Jennings: Oil Operations

Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...

Day In a Page

War with Isis: The West needs more than a White Knight

The West needs more than a White Knight

Despite billions spent on weapons, the US has not been able to counter Isis's gruesome tactics, says Patrick Cockburn
Return to Helmand: Private Davey Graham recalls the day he was shot by the Taliban

'The day I was shot by the Taliban'

Private Davey Graham was shot five times during an ambush in 2007 - it was the first, controversial photograph to show the dangers our soldiers faced in Helmand province
Revealed: the best and worst airlines for delays

Revealed: the best and worst airlines for delays

Many flyers are failing to claim compensation to which they are entitled, a new survey has found
The stories that defined 2014: From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions

The stories that defined 2014

From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions
Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations

Disaster looming? Now you know where to head...

Which British city has become the first to be awarded special 'resilience' status by the UN?
Finally, a diet that works: Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced

Finally, a diet that works

Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced
Say it with... lyrics: The power of song was never greater, according to our internet searches

Say it with... lyrics

The power of song was never greater, according to our internet searches
Professor Danielle George: On a mission to bring back the art of 'thinkering'

The joys of 'thinkering'

Professor Danielle George on why we have to nurture tomorrow's scientists today
Monique Roffey: The author on father figures, the nation's narcissism and New Year reflections

Monique Roffey interview

The author on father figures, the nation's narcissism and New Year reflections
Introducing my anti-heroes of 2014

Introducing my anti-heroes of 2014

Their outrageousness and originality makes the world a bit more interesting, says Ellen E Jones
DJ Taylor: Good taste? It's all a matter of timing...

Good taste? It's all a matter of timing...

It has been hard to form generally accepted cultural standards since the middle of the 19th century – and the disintegration is only going to accelerate, says DJ Taylor
Olivia Jacobs & Ben Caplan: 'Ben thought the play was called 'Christian Love'. It was 'Christie in Love' - about a necrophiliac serial killer'

How we met

Olivia Jacobs and Ben Caplan
Bill Granger recipes: Our chef's breakfasts will revitalise you in time for the New Year

Bill Granger's healthy breakfasts

Our chef's healthy recipes are perfect if you've overindulged during the festive season
Transfer guide: From Arsenal to West Ham - what does your club need in the January transfer window?

Who does your club need in the transfer window?

Most Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
The Last Word: From aliens at FA to yak’s milk in the Tour, here’s to 2015

Michael Calvin's Last Word

From aliens at FA to yak’s milk in the Tour, here’s to 2015